Clinical trials: Lymphoid Leukemia
Leukemia, Acute Lymphoblastic
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
B-precursor ALL is an aggressive malignant disease. Therapy is usually stratified according to risk characteristics to ensure that appropriate treatment is administered to patients with high-risk of relapse.
- Trial name
- NCT02393859
- Testing
- Blinatumomab, Dexamethasone, Vincrisitne
- Where
- 103 sites in Argentina, Australia and 22 more
- Volunteers
- 111 people
- Sponsor
- Amgen
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence
Childhood Acute Lymphoblastic Leukaemia: Follow-Up
Over the past decades, advances in treatment have led to an increasing number of children who survive cancer, resulting in a growing population of childhood cancer survivors.
- Trial name
- NCT03545659
- Testing
- Mode of relapse/SMN detection
- Where
- 5 sites in Denmark, Finland and 3 more
- Volunteers
- 277 people
- Sponsor
- University of Aarhus
Pediatric ALL
Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia
The goal of this clinical trial is to explore the minimum effective concentration and volume of ropivacaine for sacral plexus anesthesia.
- Trial name
- NCT06711679
- Testing
- Low-dose ropivacaine, Medium-dose of ropivacaine, High-dose ropivacaine
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Yilin Zhao
Osteoporosis, Osteonecrosis
Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study
This study explores the effect of zoledronic acid on incident vertebral fractures and osteonecrotic lesions in children recently diagnosed with acute lymphoblastic leukemia.
- Conditions
- Osteoporosis, Osteonecrosis, Acute Lymphoblastic Leukemia
- Trial name
- NCT02632903
- Testing
- Zoledronic acid
- Where
- Canada
- Sponsor
- Children's Hospital of Eastern Ontario
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia
ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.
The objective of this study is to assess the safety and efficacy of a immunophenotype-adapted approach using CAR T-cells in patients with high-risk, refractory or relapsed B-lineage acute lymphoblastic leukemia (B-ALL).
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute Adult, Lymphoblastic Leukemia in Children
- Trial name
- ALaCART (NCT05038696)
- Testing
- CAR T-cell therapy
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- National University Hospital, Singapore
B-cell Acute Lymphocytic Leukemia
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.
- Trial name
- NCT03064269
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT05334823
- Testing
- pCAR-19B cells
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Acute Lymphoblastic Leukemia
Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia
The goal of this observational study is to quantify the burden of particularly severe, long-term adverse effects in childhood acute lymphoblastic leukemia (ALL) survivors.
- Trial name
- NCT05639673
- Where
- Denmark
- Volunteers
- 5,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Leukemia, B-cell, Lymphoma, B-Cell
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.
- Trial name
- NCT04649983
- Testing
- CD19 and CD22 targeted CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Acute Lymphoblastic Leukemia
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
The objective of current protocol is try improve the results of chemotherapy treatment in patients with ALL wich is not indicated the peripheral stem cell transplant in first remission, with an intensive consolidation follow by…
- Trial name
- NCT00494897
- Testing
- Asparaginase, Cyclophosphamide, Cytarabine
- Where
- 87 sites in Spain
- Volunteers
- 374 people
- Sponsor
- PETHEMA Foundation
Acute Lymphoblastic Leukemia, B Cell Lymphoma
Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies
This is the second stage of the previous anti-CD19 CAR-T therapy (NCT02965092). The study aims to evaluate the safety and efficacy of consolidative allo-HSCT following CAR-T therapy in patients with relapsed or refractory B cell…
- Trial name
- NCT03366350
- Testing
- Allogeneic hematological stem cell transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Wuhan Sian Medical Technology Co., Ltd
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma…
- Trial name
- NCT02518113
- Testing
- LY3039478, Dexamethasone
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
CD19-positive ALL
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/CD22 bispecific chimeric antigen receptors (CARs) T cell therapy for CD19-positive Acute Lymphoblastic Leukemia.
- Trial name
- NCT04303520
- Testing
- anti-CD19/CD22 CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Pediatric ALL, Transplant; Failure, Heart
HIIT in Pediatric Heart Transplant Recipients (MedBIKE™)
Heart transplantation is the long-term treatment for children and adults with advanced heart failure. Post-transplant outcomes have improved over time, such that 50% of pediatric heart transplant recipients (HTR) remain alive…
- Trial name
- NCT05451979
- Testing
- MedBIKE HIIT
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of Alberta
Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma
506U78 in Treating Patients With Refractory Hematologic Cancer
Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT00002970
- Testing
- nelarabine, methotrexate, cytarabine
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
This is a phase l, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
- Trial name
- CARTHIAE-1 (NCT05705570)
- Testing
- Cyclophosphamide, Fludarabine, Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Nelson Hamerschlak
Critical Care, Hypoxia
Conservative Versus Liberal Oxygenation Targets in Critically Ill Children
A feasibility study to determine if it is possible to perform a safe, adequately powered, and affordable multi-centre study in critically ill children comparing current practice of liberal targets for systemic oxygen levels with…
- Conditions
- Critical Care, Hypoxia, Pediatric ALL
- Trial name
- Oxy-PICU (NCT03040570)
- Testing
- Conservative oxygenation target, Liberal oxygenation target
- Where
- 3 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Acute Lymphoid Leukemia, Acute Myeloid Leukemia in Children
Study of the Medullary Microenvironment in Acute Childhood Leukemia
Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child.
- Trial name
- MILA (NCT05792007)
- Testing
- Biological sampling in patients, Biological sampling in control patients
- Where
- 3 sites in France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Leukemia
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim and sargramostim may increase the number of immune cells found…
- Trial name
- NCT00053131
- Testing
- filgrastim, sargramostim, cytarabine
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
T-lymphoblastic Lymphoma, NK/T Cell Lymphoma
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
This study is designed to explore the safety and efficacy of CD7 CAR-T Cells for patients with relapse/refractory CD7+ NK/T cell lymphoma ,T-lymphoblastic lymphoma and Acute Lymphocytic Leukemia.
- Conditions
- T-lymphoblastic Lymphoma, NK/T Cell Lymphoma, Acute Lymphocytic Leukemia
- Trial name
- NCT04004637
- Testing
- CD7 CAR-T cells infusion
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.